Faculty Profiles - HATTORI Norifumi

Papers - HATTORI Norifumi

Division display 161 - 180 of about 220 ／ All the affair displays >>

当院における進行再発大腸癌に対するAflibercept治療成績の検討

大原規彰, 上原圭介, 相場利貞, 小倉淳司, 佐藤雄介, 中山吾郎, 服部憲史, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会総会 Vol. 75回 page： P128 - 3 2020.12

局所再発直腸癌に対する骨盤内臓全摘術後の治療成績

山東雅紀, 上原圭介, 相場利貞, 小倉淳司, 佐藤雄介, 中山吾郎, 服部憲史, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会総会 Vol. 75回 page： P181 - 7 2020.12

局所再発直腸癌および肝転移切除後の長期生存例に発症した下行結腸ストマ部癌の一例

村田悠記, 上原圭介, 相場利貞, 小倉淳司, 山東雅紀, 田中綾, 大原規彰, 神野孝徳, 佐藤雄三, 服部憲史, 中山吾郎, 江畑智希, 小寺泰弘, 梛野正人

日本ストーマ・排泄リハビリテーション学会誌 Vol. 36 ( 3 ) page： 128 - 128 2020.12

大腸切除術中のICG angiographyによる腸管血流描出時間の検討

田中綾, 上原圭介, 相場利貞, 小倉淳司, 佐藤雄介, 服部憲史, 中山吾郎, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会総会 Vol. 75回 page： O18 - 4 2020.12

What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer? International journal

Atsushi Ogura, Kay Uehara, Toshisada Aiba, Norifumi Hattori, Goro Nakayama, Osamu Maeda, Yuichi Ando, Yasuhiro Kodera, Tomoki Ebata, Masato Nagino

International journal of colorectal disease Vol. 35 ( 11 ) page： 2073 - 2080 2020.11

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: Systemic chemotherapy (SC) before surgery is a potential treatment to improve survival in patients with advanced rectal cancer. However, the impact of SC on lateral lymph nodes (LLNs) remains unclear. METHODS: A total of 78 patients with stage II/III low rectal cancer, who received 3-month oxaliplatin-based SC followed by LLN dissection (LLND) in principle, were analysed retrospectively. "Total lateral lymph node metastases (tLLNMs)" was defined as having either pathological LLNMs (pLLNMs) or lateral local recurrences (LLRs). Patients with the maximum short-axis size of LLNs ≥ 7 mm were classified into the swollen group (n = 21). RESULTS: In the total cohort, tLLNMs included 6 pLLNMs (7.7%) and 2 LLRs (2.6%). In the non-swollen group, no patients had pLLNMs, but one had LLR (1.8%). In the swollen group, pLLNMs and LLRs were detected in 6 (28.6%) and 1 (4.8%), respectively. The swollen group was an independent risk factor for tLLNMs (P < 0.001), leading to the significantly worse 5-year relapse-free survival (RFS) of 52.4% than the others. CONCLUSION: For patients without swollen LLNs, SC could allow for omission both of lateral irradiation and LLND. For patients with swollen LLNs, the lateral local control was favourable after SC and LLND without chemoradiotherapy (CRT); however, oxaliplatin-based SC might be insufficient to improve survival, requiring more intensive chemotherapy. CRT should be indicated according to the other risk factors of central local recurrence, although the swollen LLNs should be removed.

DOI： 10.1007/s00384-020-03690-z

Web of Science

PubMed

An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. Reviewed International journal

Mitsuro Kanda, Masahiko Koike, Naoki Iwata, Dai Shimizu, Chie Tanaka, Norifumi Hattori, Masamichi Hayashi, Suguru Yamada, Kenji Omae, Goro Nakayama, Yasuhiro Kodera

The oncologist Vol. 25 ( 11 ) page： E1650 - E1654 2020.11

Language：English Publishing type：Research paper (scientific journal)

LESSONS LEARNED: Two courses of neoadjuvant therapy using S-1 plus cisplatin for clinical stage III esophageal squamous cell carcinoma did not achieve expected response rate according to endoscopic evaluation of primary tumors. Subsequent esophagectomy was safely performed. BACKGROUND: In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC). However, 5-fluorouracil plus cisplatin does not benefit cohorts with clinical stage III ESCC, suggesting the need for a more effective regimen. METHODS: A single-arm, open-label phase II trial was conducted to evaluate the safety and efficacy of two courses of neoadjuvant chemotherapy using S-1 plus cisplatin (NAC-SP) for clinical stage III ESCC. The primary endpoint was overall response rate as defined by endoscopic evaluation of primary tumors. RESULTS: We enrolled 26 patients. The completion rate for the two courses of NAC-SP was 61.5%. Grade 3 or higher adverse events were experienced by 38.4% of patients. The treatment response rate according to endoscopic findings, acquired before the second course, was 34.6% and below the expected level (55.0%). The morbidity rate of patients who underwent radical subtotal esophagectomy (96.2%) was 32.0%. Repeat surgery was unnecessary, and surgery-associated deaths did not occur. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 84.6% and 92.2%, respectively. CONCLUSION: We demonstrate safety of NAC-SP, but not its efficacy, for patients with clinical stage III ESCC. Subsequent esophagectomy was safely performed.

DOI： 10.1634/theoncologist.2020-0546

Web of Science

PubMed

胃診断

中村俊介, 神田光郎, 清水大, 澤木康一, 田中千恵, 服部憲史, 園原史訓, 高見秀樹, 猪川祥邦, 林真路, 山田豪, 小池聖彦, 小寺泰弘

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 296 - 296 2020.11

膵臓悪性

山田豪, 高見秀樹, 園原史訓, 猪川祥邦, 林真路, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 藤井努, 小寺泰弘

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 316 - 316 2020.11

大腸症例(悪性)

村田悠記, 上原圭, 相場利貞, 小倉淳司, 山東雅紀, 田中綾, 大原規彰, 神野孝徳, 佐藤雄介, 服部憲史, 中山吾郎, 横山幸浩, 國料俊男, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 210 - 210 2020.11

肝臓集学的治療

米川佳彦, 上原圭, 相場利貞, 小倉淳司, 山東雅紀, 田中綾, 大原規彰, 村田悠記, 神野孝徳, 佐藤雄介, 服部憲史, 中山吾郎, 横山幸浩, 國料俊男, 伊神剛, 深谷昌秀, 水野隆史, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 254 - 254 2020.11

予定残肝ICG消失率(ICG-Krem)の術後肝不全発症予測因子としての有用性

砂川祐輝, 山田豪, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 58回 page： O60 - 4 2020.10

【大腸癌術前治療up-to-date】大腸癌術前化学療法のup-to-date

上原圭, 相場利貞, 小倉淳司, 村田悠記, 佐藤雄介, 服部憲史, 中山吾郎, 小寺泰弘, 江畑智希

日本大腸肛門病学会雑誌 Vol. 73 ( 10 ) page： 417 - 423 2020.10

Language：Japanese Publisher：(一社)日本大腸肛門病学会

本邦での遠隔転移を伴わない局所進行大腸癌の標準治療は手術+術後補助化学療法であるものの,その治療成績が満足できるものとはいい難い.一方,近年の著しい薬物療法の進歩を背景に,術前化学療法(NAC)は日常臨床の中で徐々に普及しているが,その長期成績は明らかでない.直腸癌に対する術前化学療法(NAC)は欧米では放射線化学療法(CRT)を省略することになり,高リスク症例では受け入れられ難い.しかし,術前治療を一般的に行って来なかった本邦では,NACは単に術後補助化学療法の前倒しであり,可能な施設に限りがあるCRTと比較して,多くの施設で受け入れられやすい.NACはCRTと比較して局所効果はやや劣るものの,生存率は遜色ない.今後は,リスク分類により個別化治療を提供していく必要がある.(著者抄録)

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01146&link_issn=&doc_id=20201202370004&doc_link_id=10.3862%2Fjcoloproctology.73.417&url=https%3A%2F%2Fdoi.org%2F10.3862%2Fjcoloproctology.73.417&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

高齢大腸癌患者に対する外科治療の成績

相場利貞, 上原圭, 小倉淳司, 山東雅紀, 田中綾, 大原規彰, 神野孝徳, 村田悠記, 佐藤雄介, 服部憲史, 中山吾郎, 横山幸浩, 國料俊男, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 江畑智希, 小寺泰弘, 梛野正人

日本消化器病学会雑誌 Vol. 117 ( 臨増大会 ) page： A717 - A717 2020.10

Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Reviewed International journal

Mitsuro Kanda, Masahiko Koike, Dai Shimizu, Chie Tanaka, Norifumi Hattori, Masamichi Hayashi, Suguru Yamada, Kenji Omae, Yasuhiro Kodera

Annals of surgical oncology Vol. 27 ( 9 ) page： 3195 - 3205 2020.9

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Recurrence after radical resection of esophageal squamous cell carcinoma (ESCC) is common. Limited evidence is available about the differences in clinical characteristics, risk factors, and prognostic significance between nodal and distant recurrence of thoracic ESCC. PATIENTS AND METHODS: We retrospectively analyzed 341 patients who underwent radical resection of thoracic ESCC and experienced (1) initial recurrence only in lymph nodes (n = 39), (2) recurrence only at distant organs (n = 57), or (3) no recurrences (n = 245) after follow-up ≥ 24 months. Clinicopathological characteristics, survival times, and risk factors were compared between the nodal and distant recurrence groups. RESULTS: The median follow-up time was 57.8 months. Metastasectomy as initial treatment for the recurrence was performed for six (15.4%) patients in the nodal recurrence group and one patient in the distant recurrence group. Compared with the nodal recurrence group, patients with distant recurrence had significantly shorter disease-free survival [hazard ratio (HR) 1.68, 95% confidence interval (CI) 1.10-2.57, P = 0.0169], postrecurrence survival (HR 1.77, 95% CI 1.01-3.10, P = 0.0476), and overall survival (HR 1.98, 95% CI 1.12-3.51, P = 0.0193). The distant recurrence group had significantly larger macroscopic tumor size and more advanced pathological T stage than the nodal recurrence group, whereas preoperative treatment, tumor location, number of fields dissected, tumor differentiation, lymphatic involvement, and vessel invasion were not significantly different between the two groups. CONCLUSIONS: Survival times and recurrence risk factors differed between patients with nodal and distant recurrence after radical resection of thoracic ESCC.

DOI： 10.1245/s10434-020-08433-6

Web of Science

PubMed

Chemotherapy-free intervalを得るため積極的に手術適応としたBRAF V600E変異型盲腸癌腹膜播種再発の1例

神野孝徳, 上原圭, 相場利貞, 小倉淳司, 田中綾, 大原規彰, 村田悠記, 鈴木優美, 三品拓也, 佐藤雄介, 服部憲史, 中山吾郎, 小寺泰弘, 江畑智希

日本大腸肛門病学会雑誌 Vol. 73 ( 9 ) page： A185 - A185 2020.9

骨盤内臓全摘術の手術手技と成績骨盤内臓全摘術の基本と応用

上原圭, 相場利貞, 小倉淳司, 田中綾, 大原規彰, 村田悠記, 鈴木優美, 三品拓也, 佐藤雄介, 服部憲史, 中山吾郎, 小寺泰弘, 江畑智希

日本大腸肛門病学会雑誌 Vol. 73 ( 9 ) page： A68 - A68 2020.9

直腸癌に対する術前治療の現状と展望下部進行直腸癌に対するpatient-adopted strategyを目指した当科の術前治療と成績

小倉淳司, 上原圭, 相場利貞, 田中綾, 大原規彰, 村田悠記, 神野孝徳, 鈴木優美, 三品拓也, 佐藤雄介, 服部憲史, 中山吾郎, 小寺泰弘, 江畑智希

日本大腸肛門病学会雑誌 Vol. 73 ( 9 ) page： A52 - A52 2020.9